Cera-Flow: Blood Circulation Short Term Study

Sponsor
Ceragem Clinical Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05469282
Collaborator
(none)
60
1
1
1.4
43.5

Study Details

Study Description

Brief Summary

The study is a single center clinical trial to evaluate the efficacy and safety of blood circulation improvement using an investigational medical device, which is a product on the market and it's name is Ceragem Master V6, for the risk group of Deep Vein Thrombosis (DVT) and the ordinary person. The study compares before and after the application by one time application.

Condition or Disease Intervention/Treatment Phase
  • Device: Blood circulation device
N/A

Detailed Description

The efficacy and safety evaluation are conducted before and after (or during) the application of the test device. The investigator shall apply an investigational device once when visiting a suitable subject for one day.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Single Center Clinical Trial to Evaluate the Efficacy and Safety of Blood Circulation Improvement Using an Investigational Medical Device (Model Name CGM MB-1701) for the Risk Group of Deep Vein Thrombosis (DVT) and the Ordinary Person
Actual Study Start Date :
Aug 19, 2022
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: blood circulation treatment

Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT) and the ordinary person

Device: Blood circulation device
Blood circulation device of CGM MB-1701 (Ceragem Master V6)

Outcome Measures

Primary Outcome Measures

  1. Peak Systolic Velocity (PSV) change [While 2 consecutive application (36 minutes) per one subject]

    Evaluate the maximum blood flow rate (PSV) change in the femoral vein when applied compared to before application of the device using ultrasonic at Visit 1

Secondary Outcome Measures

  1. Antero-posterior (AP) diameter [While 2 consecutive application (36 minutes) per one subject]

    Evaluate the the maximum AP diameter change of the femoral vein when applied compared to before the device is applied using ultrasonic at Visit 1.

  2. Cross Sectional Area [While 2 consecutive application (36 minutes) per one subject]

    Evaluate the maximum CSA area change of the femoral vein when applied compare to before the device is applied using ultrasonic at Visti 1.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria for all subjects; 1. Adult men and women over 19 years of age 2. Subjects who have not been diagnosed with deep vein thrombosis in the lower extremities through the following test results prior to the application of medical devices.

  1. Subjects diagnosed by Doppler ultrasonography as having no blood clots in the femoral vein and the vena poplitea

  2. D-dimer negative test result

  3. Subjects who fully understand the purpose and procedure of the study and wish to participate in clinical trials with voluntary consent

Additional Inclusion Critetia for the DVT risk subjects;

  1. Subjects have two or more points of venous thromboembolism (hereinafter referred to as VTE) clinical prediction score (Two-level wells scroe) at the time of screening
Exclusion Criteria:
  1. Subjects who complain of a decrease in the sensation of the lower extremities or who is unable to feel the sensation of pain

  2. Subjects who have inflammation or trauma on the skin that directly touches the device

Contacts and Locations

Locations

Site City State Country Postal Code
1 Presbyterian Medical Center Jeonju Korea, Republic of

Sponsors and Collaborators

  • Ceragem Clinical Inc.

Investigators

  • Principal Investigator: Yong Soon Yoon, MD, Presbyterian medical center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ceragem Clinical Inc.
ClinicalTrials.gov Identifier:
NCT05469282
Other Study ID Numbers:
  • 2022-06-043
First Posted:
Jul 21, 2022
Last Update Posted:
Aug 23, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2022